Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban
I
n the past several years, three new oral an ticoagulants-dabigatran etexilate (Pra daxa), rivaroxaban (Xarelto), and apixaban (Eliquis)-have been approved for use in the United States. These longawaited agents are appealing because they are easy to use, do not require laboratory monitoring, and have demonstrated equivalence, or in some cases, superiority to warfarin in preventing stroke or systemic embolism in atrisk populations. [1] [2] [3] [4] However, unlike warfarin, they have no spe cific reversal agents. How then should one manage spontaneous bleeding problems and those due to drug overdose, and how can we quickly reverse an ticoagulation if emergency surgery is needed?
For these reasons, physicians and pa tients have been wary of these agents. How ever, with a systematic approach based on an understand ing of the properties of these drugs, the appro priate use and interpretation of coagulation tests, and awareness of avail able therapeutic strategies, physicians can more confidently provide care for patients who require urgent reversal of anticoagulant effects.
Here, we review the available litera ture and suggest practical strategies for man agement based on an understanding of the pharmaco kinetic and pharmacodynamic ef fects of these drugs and our current knowledge of the coagu lation tests.
NEW ORAL ANTICOAGULANTS
And the numbers are staggering. The es timated prevalence of atrial fibrillation in the United States was 3.03 million in 2005 and is projected to increase to 7.56 million by 2050. 5 Ischemic stroke is the most serious complica tion of atrial fibrillation, which accounts for 23.5% of strokes in pa tients ages 80 through 89 according to Framingham data. 6 Venous thromboem bolism accounts for 900,000 inci dent or recur rent fatal and nonfatal events in the United States yearly. 7 
■ HOW THE NEW AGENTS BLOCK COAGULATION
Thrombin (factor IIa), a serine protease, is central to the process of clot formation dur ing hemostasis. It activates factors V, VIII, and XI (thus generating more thrombin), catalyzes the conversion of fibrinogen to fibrin, and stimulates platelet aggregation. Its role in the final steps of the coagulation cascade has made it a target for new direct thrombin inhibitors such as dabigatran. Factor Xa is a serine protease that plays a central role in the coagulation cascade. It is a desirable target for anticoagulation because it is the convergence point for the extrinsic and the intrinsic coagulation pathways. It con verts prothrombin to thrombin. Rivaroxaban and apixaban are direct factor Xa inhibitors (FIGURE 1).
Dabigatran, a direct thrombin inhibitor
Dabigatran etexilate is a synthetic, orally available prodrug that is rapidly absorbed and converted by esterases to its active form, da bigatran, a potent direct inhibitor of both free thrombin and clotbound throm bin. 8 Plasma levels of dabigatran peak within 2 hours of administration, and its halflife is 14 to 17 hours. 9 Dabigatran is eliminated mainly via the kidneys, with more that 80% of the drug excreted unchanged in the urine (TABLE 1) .
Rivaroxaban, a factor Xa inhibitor
Rivaroxaban is a potent, selective, direct fac tor Xa inhibitor.
Plasma levels of rivaroxaban peak 2 to 3 hours after administration, and it is cleared with a terminal halflife of 7 to 11 hours. 10, 11 Rivaroxaban is eliminated by the kidneys and in the feces. The kidneys eliminate onethird of the active drug unchanged and anoth er one third as inactive metabolites. The re maining onethird is metabolized by the liver and then excreted in the feces. Rivaroxaban has a predict able and dosedependent phar macodynamic and pharmacokinetic profile that is not affected by age, sex, or body weight ( 
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Apixaban, an oral factor Xa inhibitor
Apixaban is a selective, direct oral factor Xa inhibitor.
Plasma levels of apixaban peak about 3 hours after administration, and its terminal halflife is 8 to 14 hours. 13 Apixaban is elimi nated by oxidative metabolism, by the kidney, and in the feces. It has predictable pharmaco dynamic and pharmacokinetic profiles and has the least renal dependence of the three agents (TABLE 1).
■ THE NEW ORAL ANTICOAGULANTS AND BLOOD COAGULATION ASSAYS
Assessment of the anticoagulant activity of the new oral anticoagulants is not necessary in routine clinical practice, but it may be use ful in planning intervention in patients with major bleeding, those with drug overdose, or those who need emergency surgery.
The activated partial thromboplastin time
The activated partial thromboplastin time (aPTT) is a measure of the activity of the in trinsic pathway of the coagulation cascade.
Dabigatran. There is a curvilinear rela tionship between the aPTT and the plasma concentration of dabigatran and other di rect thrombin inhibitors, although the aPTT prolongation appears to vary with different reagents and coagulometers.
9,14,15 However, Stangier et al 9 found a linear relationship be tween the aPTT and the square root of the dabigatran plasma concentration.
Rivaroxaban prolongs the aPTT in a dose dependent manner, but there is no standard for calibration of this assay. Hence, the aPTT is not recommended for monitoring rivaroxa ban in clinical practice.
Apixaban may also prolong the aPTT, but there are limited data on its reactivity with different reagents.
The prothrombin time and international normalized ratio
The prothrombin time and international nor malized ratio (INR) are measures of the ex trinsic pathway of the coagulation cascade.
Dabigatran. The INR has a linear re sponse to the dabigatran concentration, but it is insensi tive. 9 Hence, it is not suitable for monitoring the anticoagulant effects of direct thrombin inhibitors.
Rivaroxaban. The prothrombin time cor relates strongly with the plasma concentration of rivaroxaban in healthy trial participants 11 and in pa tients undergoing total hip arthro plasty or to tal knee arthroplasty. 16 Samama et al 17 noted that, unlike with vitamin K antago nists, the INR cannot be used to monitor pa tients on rivaroxaban because the prothrom bin time re sults varied with different reagents. They used a standard calibration curve to ex Management of bleeding from these novel agents should begin with preventing bleeding in the first place press the prothrombin time results in plasma concen trations of rivaroxaban rather than in seconds or the INR. Apixaban increases the INR in a dose dependent manner. 18 Its effect on different reagents remains unknown.
The thrombin time
The thrombin time reflects the activity of thrombin in the plasma. The amount of thrombin and the concentration of thrombin inhibitors in the plasma sample determine the time to clot formation.
Dabigatran. The thrombin time displays a linear doseresponse to dabigatran, but only over the range of therapeutic concentrations. At a dabiga tran concentration greater than 600 ng/mL, the test often exceeds the maxi mum measurement time of coagulometers. 9 Hence, this test is too sensitive for emergency moni toring, especially in cases of drug over dose. However, it is well suited for determining if any dabigatran is present.
Rivaroxaban and apixaban have no effect on the thrombin time.
The Hemoclot direct thrombin inhibitor as say and dabigatran
The Hemoclot direct thrombin inhibitor as say (Hyphen BioMed, France) is a sensitive diluted thrombin time assay that can be used for quantitative measurement of dabigatran activity in plasma. This test is based on inhi bition of a constant amount of highly purified human alphathrombin by adding it to diluted test plasma (1:8 to 1:20) mixed with normal pooled human plasma. 19, 20 Stangier et al 19 found that the Hemo clot assay was suitable for calculating a wide range of dabigatran concentrations up to 4,000 nmol/L (1,886 ng/mL). Although this finding has not been confirmed in larger studies, this test may provide a rapid and ac curate assess ment of dabigatran's anticoagu lant activity in cases of emergency surgery or overdose.
The ecarin clotting time and dabigatran
The ecarin clotting time is a measure of the activity of direct thrombin inhibitors, but not the factor Xa inhibitors.
Ecarin is a highly purified metalloprotease isolated from the venom of a snake, Echis car inatus, and it generates meizothrombin from prothrombin. 21 Meizothrombin facilitates clot formation by converting fibrinogen to fi brin and, like thrombin, it can be inactivated by direct thrombin inhibitors, thereby pro longing the clotting time.
The limitations of the ecarin clotting time include dependence on the plasma levels of fibrinogen and prothrombin.
The ecarin chromogenic assay and dabiga tran
The ecarin chromogenic assay is an improve ment on the principle of the ecarin clotting time that can be used to measure the activ ity of direct thrombin inhibitors. 22 In this test, ecarin is added to a plasma sample to generate meizothrombin, and the amidolytic activity of meizothrombin towards a chromogenic sub strate is then determined.
Results of the ecarin chromogenic assay are not influenced by the levels of fibrinogen or prothrombin. Another advantage is that this assay can be used in automated and man ual analyzers, thus enabling its use at the bed side. However, to our knowledge, it is not be ing regularly used to monitor direct throm bin inhibitors in the clinical setting, and there is no standard calibration of the ecarin clot ting time method.
Assays of factor Xa activity
A variety of assays to monitor the antico agulant activity of factor Xa inhibitors have been proposed. [23] [24] [25] All measure inhibition of the activity of factor Xa using methods simi lar to those used in monitoring heparin levels. All require calibrators with a known concen tration of the Xa inhibitor; many are easily adapted for laboratories currently providing measurement of factor Xa inhibition from heparin. 23 These assays have been suggested as a better indicator of plasma concentration of factor Xa inhibitor drugs than the prothrom bin time. 25 
■ CONTROLLING BLEEDING IN PATIENTS ON THE NEW ORAL ANTICOAGULANTS
Bleeding is an anticipated adverse event in patients taking anticoagulants. It is associ ated with significant morbidity and risk of death.
26,27
Renal function is important in managing patients on the new oral anticoagulants
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Many physicians still have limited experi ence with using the new oral anticoagulants and managing the attendant bleed ing risks. Hence, we recommend that every health in stitution have a treatment policy or algorithm to guide all clinical staff in the man agement of such emergencies.
Prevention of bleeding
Management of bleeding from these agents should begin with preventing bleeding in the first place.
The physician should adhere to the recom mended dosages of these medications. Studies have shown that the plasma concentration of these drugs and the risk of bleeding increase with increasing dosage. 1, 28, 29 In addition, these medications should be used for the shortest time for which antico agulation is required, especially when used for preventing deep vein thrombosis. Prolonged use increases the risk of bleeding. 30, 31 Most patients who need anticoagulation have comorbidities such as heart failure, re nal failure, diabetes mellitus, and hyperten sion. Although the kidneys play a major role in the excretion of dabigatran and, to some extent, rivaroxaban and apixaban, patients with se vere renal impairment were excluded from the major trials of all three drugs. [1] [2] [3] Hence, to avoid excessive drug accumula tion and bleeding, these medi cations should not be used in such patients pending further studies. Further, patients taking these medi cations should be closely followed to detect new clini cal situations, such as acute renal failure, that will necessitate their discontinu ation or dose adjustment.
If surgery is needed
If a patient taking a new oral anticoagulant needs to undergo elective surgery, it is impor tant to temporarily discontinue the drug, as sess the risk of bleeding, and test for renal im pairment.
Renal impairment is particularly relevant in the case of dabigatran, since more than 80% of the unchanged drug is cleared by the kidneys. Decreasing the dose, prolonging the dosing interval, or both have been suggested as means to reduce the risk of bleeding in pa tients with renal impairment who are taking dabiga tran. 32, 33 Patients with normal renal function undergoing lowrisk surgery should discon tinue dabigatran at least 24 hours before the surgery. If the creatinine clearance is 31 to 50 mL/min, inclusively, the last dose should be at least 48 hours before the procedure for low risk surgery, and 4 days before a procedure that poses a high risk of bleeding. [32] [33] [34] Some experts have given the same recommendations for ri varoxaban and apixaban (TABLE 2) . 34 The aPTT and prothrombin time are read ily available tests, but they cannot determine the residual anticoagulant effects of dabiga tran, rivaroxaban, or apixaban. However, in many (but not all) cases, a normal aPTT sug gests that the hemostatic function is not im paired by dabigatran, and a normal prothrom bin time or an absence of antifactor Xa activity would similarly exclude hemostatic dysfunc tion caused by rivaroxaban or apixa ban. These tests are potentially useful as ad juncts before surgical procedures that require complete he mostasis.
Furthermore, a normal thrombin time rules out the presence of a significant amount of dabigatran. Therefore, a normal thrombin time might be particularly useful in a patient undergoing a highrisk intervention such as epidural cannulation or neurosurgery and who is normally receiving dabigatran.
Every hospital needs a policy or algorithm for managing bleeding emergencies Major and lifethreatening bleeding (eg, intracerebral hemorrhage) requires aggres sive treatment in the intensive care unit, withdrawal of the anticoagulant, mechanical compression of the bleeding site if accessible, fluid replacement and blood transfusion as appropriate, and interventional procedures. Nonspecific reversal agents might be consid ered in patients with major or lifethreatening bleeding.
The halflife of dabigatran after multiple doses is approximately 14 to 17 hours and is not dosedependent. 9 Hence, if there is no active bleeding after a dabigatran overdose, stopping the drug may be sufficient. Since the pharmacodynamic effect of dabigatran de clines in parallel to its plasma concentration, urgent but not emergency surgery may need to be delayed for only about 12 hours from the last dose of dabigatran.
The 2011 American College of Cardiol ogy Foundation/American Heart Association guidelines recommend that patients with se vere hemorrhage resulting from dabigatran should receive supportive therapy, including transfusion of freshfrozen plasma, transfu sion of packed red blood cells, or surgical interven tion if appropriate. 35 However, trans fusion of freshfrozen plasma is debatable be cause there is no evidence to support its use in this situ ation. While freshfrozen plasma may be use ful in cases of coagulation factor deple tion, it does not effectively reverse inhibition of co agulation factors. Off-label use of nonspecific hemostatic agents To date, no specific agent has been demon strated to reverse excessive bleeding in pa tients taking the new oral anticoagulants. However, in view of their procoagulant capa bilities, nonspecific hemostatic agents have been suggested for use in reversal of major bleeding resulting from these drugs. [37] [38] [39] Ex amples are:
TABLE 3
Managing bleeding in patients receiving dabigatran, apixaban, or rivaroxaban
Strategies to minimize risk of bleeding
Review all clinical problems in the patient (eg, degree of renal impairment) before starting a patient on dabigatran, apixaban, or rivaroxaban Prescribe drugs at recommended dosages and limit duration to the short est time for which anticoagulation is needed Periodically review clinical conditions (eg, acute renal failure) that may warrant abrupt discontinuation of anticoagulation or dose adjustment Stratify bleeding risk preoperatively and discontinue anticoagulation before surgery or procedures (when appropriate)
Use commonly available anticoagulation tests before procedures with high risk of bleeding: A normal thrombin time and normal activated partial thromboplastin time will, in many cases, imply no hemostatic dysfunction due to dabigatran A normal prothrombin time or an undetectable anti-factor Xa activity would exclude hemostatic dysfunction due to rivaroxaban or apixaban in many cases 
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Recombinant factor VIIa (NovoSeven) initiates thrombin generation by activat ing factor X.
Four-factor prothrombin complex concentrate (Beriplex, recently approved in the United States) contains relatively large amounts of four nonactive vitamin Kdepen dent procoagulant factors (factors II, VII, IX, and X) that stimulate thrombin formation.
Three-factor prothrombin complex concentrate (Bebulin VH and Profil nine SD) contains low amounts of nonactive factor VII relative to factors II, IX, and X. In some cen ters a fourfactor equivalent is produced by transfusion of a threefactor product with the addition of small amounts of recombi nant fac tor VIIa or freshfrozen plasma to replace the missing factor VII.
40
Activated prothrombin complex concentrate (FEIBA NF) contains activated factor VII and factors II, IX, and X, mainly in nonactivat ed form. 36 Therefore, it combines the effect of both recombinant factor VIIa and fourfactor prothrombin complex concentrate.
37
Studies of nonspecific hemostatic agents
In a study of rats infused with high doses of dabigatran, van Ryn et al 38 observed that acti vated prothrombin complex concentrate at a dose of 50 or 100 U/kg and recombinant fac tor VIIa at a dose of 0.1 or 0.5 mg/kg reduced the rattail bleeding time in a dosedependent manner but not the blood loss, compared with controls, even with a higher dose of recom binant factor VIIa (1 mg/kg). Recombinant factor VIIa also re versed the prolonged aPTT induced by dabig atran, whereas activated pro thrombin complex concentrate did not. They suggested that recombinant factor VIIa and activated prothrombin complex concentrate may be potential antidotes for dabigatranin duced severe bleeding in humans.
In an ex vivo study of healthy people who took a single dose of dabigatran 150 mg or rivaroxaban 20 mg, Marlu et al 37 found that activated prothrombin complex concentrate and fourfactor prothrombin complex concen trate could be reasonable antidotes to these drugs.
Dabigatranassociated bleeding after car diac surgery in humans has been successfully managed with hemodialysis and recombinant factor VIIa, although the efficacy of the latter cannot be individually assessed in the study. 41 In a randomized placebocontrolled trial aimed at reversing rivaroxaban and dabiga tran in healthy participants, Ee renberg et al 39 showed that fourfactor prothrombin complex concentrate at a dose of 50 IU/kg reversed prolongation of the pro thrombin time and de creased the endogenous thrombin potential in those who received rivaroxaban, but it failed to reverse the aPTT, the endogenous throm bin potential, and thrombin time in those who received da bigatran.
However, Marlu et al reported that four factor prothrombin complex concentrate at three doses (12.5 U/kg, 25 U/kg, and 50 U/kg)-or better still, activated prothrombin complex concentrate (40-80 U/kg)-could be a useful antidote to dabigatran. 37 It is important to note that the healthy participants in the Eerenberg et al study 39 took dabigatran 150 mg twice daily and rivaroxa ban 20 mg daily for 2.5 days, whereas those in the Marlu et al study 37 took the same dose of each medication, but only once.
The threefactor prothrombin complex concentrate products have been shown to be less effective than fourfactor ones in reversing supratherapeutic INRs in patients with war farin overdose, but whether this will be true with the new oral anticoagulants remains un known. Furthermore, the fourfactor concen trates effectively reversed warfarininduced coagulopathy and bleeding in patients, 42 but to our knowledge, the same is yet to be dem onstrated in bleeding related to the newer agents.
Other measures
Gastric lavage or the administration of activat ed charcoal (or in some cases both) may reduce drug absorp tion if done within 2 or 3 hours of drug ingestion (TABLE 1) . Because it is lipophilic, more than 99.9% of dabigatran etexilate was adsorbed by activated charcoal from water prepared to simulate gastric fluid in an in vitro experiment by van Ryn et al. 43 This has not been tested in patients, and no similar study has been done for rivaroxaban or apixaban. However, use of charcoal in cases of recent ingestion, particu larly with intentional overdose of these agents, seems reasonable.
Assessing the severity of bleeding is the key to managing bleeding complications Hemodialysis may reverse the anticoagu lant effects of dabigatran overdose or severe bleeding because only about 35% of dabiga tran is bound to plasma proteins (TABLE 1) . In a singlecenter study, 50 mg of dabigatran etexilate was given orally to six patients with endstage renal disease before dialysis, and the mean fraction of the drug removed by the dia lyzer was 62% at 2 hours and 68% at 4 hours. 32 This study suggests that hemodialysis may be useful to accelerate the removal of the drug in cases of lifethreatening bleeding.
Rivaroxaban and apixaban are not dia lyzable: the plasma protein binding of rivar oxaban is 95% and that of apixaban is 87%.
■ FUTURE DIRECTIONS
Because the new oral anticoagulants, unlike warfarin, have a wide therapeutic window, routine anticoagulant monitoring is not need ed and might be misleading. However, there are times when monitoring might be useful; at such times, a validated, widely available, eas ily understood test would be good to havebut we don't have it-at least not yet.
Therapeutic ranges for the aPTT have been established empirically for heparin in various indications. 44 Additional study is needed to determine if an appropriate aPTT range can be determined for the new oral an ticoagulants, particularly dabigatran.
Similarly, as with lowmolecularweight heparins, antifactor Xa activity monitoring may become a more available validated means of testing for exposure to rivaroxaban and apixa ban. More promising, using concepts derived from the development of the INR for warfarin monitoring, 45 Tripodi et al 46 have derived nor malized INRlike assays to report rivaroxaban levels. A standardized schema for reporting re sults is being developed. 46 Studies are required to determine if and how this assay may be useful. Initial trials in this regard are encour aging. 47 Finally, the thrombotic risk associated with the use of nonspecific prohemostatic agents is unknown. 37, 48 Additional studies are required to standardize their dosages, frequency of ad ministration, and duration of action, as well as to quantify their complications in bleeding patients.
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